Bisphosphonate treatment in ochronotic osteoporotic patients

Clinical Rheumatology

Volumn 26, Issue 5, 2007, Pages 729-735

  Aliberti, Giuseppe ^a,b   Pulignano, Isabella ^a   Pisani, Daniela ^a   March, Massimiliano Rocchietti ^a   Del Porto, Flavia ^a   Proietta, Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alendronate; Alkaptonuria; Bisphosphonates; Ochronosis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; COLLAGEN; GLUCONOLACTATE CALCIUM; HOMOGENTISIC ACID; POLYMER;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE DENSITY; BONE INJURY; BONE MATRIX; CASE REPORT; CELL VIABILITY; CLINICAL FEATURE; CROSS LINKING; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; OCHRONOSIS; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DEFECT; TREATMENT DURATION; TREATMENT REFUSAL;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMUR; HUMANS; MALE; MIDDLE AGED; OCHRONOSIS; OSTEOPOROSIS;

EID: 34147123774     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0390-3     Document Type: Article

References (20)

1. Pollak MR, Chou YHW, Cerda JJ, Steinmann B, La Du BN, Seidman JG et al (1993) Homozygosity mapping of the gene for alkaptonuria to 3q2. Nat Genet 5:201-204
2. Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL et al (2002) Natural history of alkaptonuria. N Engl J Med 347:2111-2121
3. Ladjouze-Rezig A, Rodriguez de Cordoba S, Aquaron R (2006) Ochronotic rheumatism in Algeria: Clinical, radiological, biological and molecular studies - a case study of 14 patients in 11 families. Joint Bone Spine 73:284-292
4. Gaines JJ (1989) The pathology of alkaptonuric ochronosis. Hum Pathol 20:40-46
5. Aliberti G, Pulignano I, Schiappoli A, Minisola S, Romagnoli E, Proietta M (2003) Bone metabolism in ochronotic patients. J Intern Med 254:296-300
6. Fleisch H (2003) Bisphosphonates in osteoporosis. Eur Spine J 12(Suppl 2):S142-S146
7. Ioannidis JPA, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, GENOMOS Study et al (2004) Differential genetic effects of ESR1 gene polymorphism on osteoporosis outcomes. JAMA 292:2105-2114
8. Liberman UA, Weiss SR, Broll J, Minnie HW, Quan H, Bell NH et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in potmenopausal osteoporosis. N Engl J Med 333:1437-1443
9. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Fracture Intervention Trial Research Group et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
10. Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M et al (2003) Alendronate treatment in men with primary osteoporosis: A three-year longitudinal study. Calcif Tissue Int 73:133-139
11. Kanis JA, Gluer CC, Committee of Scientific Advisors, International Osteoporosis Foundation (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192-202
12. WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 843:1-129
13. Hanson J (1997) Standardization of femur BMD (letter). J Bone Miner Res 12:1316-1317
14. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J et al (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:1318-1321
15. Tuck SP, Francis RM (2002) Osteoporosis. Postgrad Med J 78:526-532
16. McClung MR (1996) Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. Bone 19:195S-198S
17. Di Franco M, Coari G, Bonucci E (2000) A morphological study of bone and articular cartilage in ochronosis. Virchows Arch 436:74-81
18. Bonucci E (1984) Matrix vesicles: Their role in calcification. In: Linde A (ed) Dentin and dentinogenesis, vol 1. CRC Press, Boca Raton, pp 135-154
19. Murray JC, Lindberg KA, Pinnell SR (1997) In vitro inhibition of chick embryo lysyl hydroxylase by homogentisic acid. A proposed connective tissue defect in alkaptonuria. J Clin Invest 59:1071-1079
20. Oxlund H, Barckman M, Ortoft G, Andreassen TT (1995) Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 17:365S-371S (Suppl)